Literature DB >> 10328037

The potential for vaccine against infection of the genital tract with Chlamydia trachomatis.

J T Grayston1, S P Wang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 10328037     DOI： 10.1097/00007435-197804000-00011

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN： 0148-5717            Impact factor:   2.830


× No keyword cloud information.
  46 in total

1.  T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans.

Authors:  L Ortiz; M Angevine; S K Kim; D Watkins; R DeMars
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.

Authors:  X Yang; R Brunham
Journal:  Can J Infect Dis       Date:  1998-03

3.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

4.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

5.  Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.

Authors:  Jennifer R Carmichael; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-24       Impact factor: 3.641

7.  Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold.

Authors:  Delia F Tifrea; Sukumar Pal; Jeff Fairman; Paola Massari; Luis M de la Maza
Journal:  NPJ Vaccines       Date:  2020-05-08       Impact factor: 7.344

8.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

9.  Genetic profiling of dendritic cells exposed to live- or ultraviolet-irradiated Chlamydia muridarum reveals marked differences in CXC chemokine profiles.

Authors:  Michelle L Zaharik; Tarun Nayar; Rick White; Caixia Ma; Bruce A Vallance; Nadine Straka; Xiaozhou Jiang; Jose Rey-Ladino; Caixia Shen; Robert C Brunham
Journal:  Immunology       Date:  2006-10-31       Impact factor: 7.397

10.  Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

Authors:  Guifeng Sun; Sukumar Pal; Joseph Weiland; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.